LSL Pharma Group (TSXV:LSL) Interest Expense: C$-3.03 Mil (TTM As of Mar. 2026)


TSXV:LSL LSL Pharma Group Inc TSXV:LSL
50 GF Score
Price C$0.32
GF Value C$0.72
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is LSL Pharma Group Interest Expense?

LSL Pharma Group TSXV:LSL 50 Interest Expense is C$-3.03 Mil as of Mar. 2026. GuruFocus rates TSXV:LSL with a GF Score™ of 50/100 and a GF Value™ of C$0.72 (Possible Value Trap). The stock has 6 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. LSL Pharma Group's interest expense for the three months ended in Mar. 2026 was C$ -0.91 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was C$-3.03 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. LSL Pharma Group's Operating Income for the three months ended in Mar. 2026 was C$ -1.84 Mil. LSL Pharma Group's Interest Expense for the three months ended in Mar. 2026 was C$ -0.91 Mil. LSL Pharma Group did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

LSL Pharma Group  (TSXV:LSL) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

LSL Pharma Group's Interest Expense for the three months ended in Mar. 2026 was C$-0.91 Mil. Its Operating Income for the three months ended in Mar. 2026 was C$-1.84 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was C$32.92 Mil.

LSL Pharma Group's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

LSL Pharma Group did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

LSL Pharma Group Interest Expense Historical Data

* Premium members only.

The historical data trend for LSL Pharma Group's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LSL Pharma Group Interest Expense Chart

LSL Pharma Group Annual Data
Trend Sep20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial -1.59 -1.27 -1.57 -1.75 -2.64

LSL Pharma Group Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.52 -0.61 -0.76 -0.75 -0.91
TSXV:LSL
50GF Score
LSL Pharma Group Inc TSXV:LSL
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LSL Pharma Group Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-3.03 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of C$-3.03 Mil mean?
LSL Pharma Group (TSXV:LSL) has a Interest Expense of C$-3.03 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on LSL Pharma Group and its competitors.
Is LSL Pharma Group's Interest Expense too high?
LSL Pharma Group's current Interest Expense is C$-3.03 Mil. Overall, LSL Pharma Group has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does LSL Pharma Group's Interest Expense compare to ZTS and UTHR?
LSL Pharma Group's Interest Expense of C$-3.03 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on LSL Pharma Group and its competitors. LSL Pharma Group's current Interest Expense is C$-3.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LSL Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, LSL Pharma Group (TSXV:LSL) is currently considered Possible Value Trap. The stock's GF Value™ is C$0.72, compared to a current price of C$0.32 — trading 56.3% below its estimated fair value. The current Interest Expense is C$-3.03 Mil. LSL Pharma Group's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For LSL Pharma Group (TSXV:LSL), the current Interest Expense is C$-3.03 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is LSL Pharma Group (TSXV:LSL) Overvalued in 2026?

Based on GuruFocus' analysis, LSL Pharma Group stock appears to be undervalued. The current stock price of C$0.32 is trading 56.3% below its estimated GF Value™ of C$0.72. GuruFocus considers LSL Pharma Group to be Possible Value Trap.

Key valuation signals for TSXV:LSL:

  • Interest Expense: C$-3.03 Mil
  • GF Value™: C$0.72 vs. price of C$0.32 (56.3% below fair value)
  • GF Score™: 50/100 with 6 warning signs

No single metric tells the full story. See the TSXV:LSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

LSL Pharma Group Business Description

Address 540, rue d\'Avaugour, Bureau 1800, Boucherville, QC, CAN, J4B 0G6
LSL Pharma Group Inc develops, manufactures and commercializes sterile pharmaceutical products, cosmetic products and natural health products. It operates in three segments CMO activities include four operating entities LSL Laboratory, Dermolab, Du-Var, and VSI; Integrated Eye-care pharmaceutical company which includes sterile Eye-care manufacturing operation; and Private Label Business includes Juno OTC which commercializes pharmaceutical products with a focus on private label, over the counter (OTC) products. It derives majority of revenue from CMO activities segment.
50GF Score

Get the complete analysis for TSXV:LSL

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.32
Price
C$0.72
GF Value